BioStock: Alligator's CEO: "I'm confident that we will strike a deal"

Alligator Bioscience is currently conducting a rights issue aimed at advancing mitazalimab towards phase III and securing a partnership. CEO Søren Bregenholt joins BioStock’s studio to discuss the recently announced cost-saving program, mitazalimab’s clinical data, and the company’s efforts to achieve a partnership for the candidate.
A number of companies are doing due diligence, says Søren Bregenholt.

Watch the interview with Alligator Bioscience at biostock.se:

https://www.biostock.se/en/2025/01/alligators-ceo-im-confident-that-we-will-strike-a-deal

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/